Evidence map›Paper›PMID 42500606›Full record

ArticleOncology letters2026

Clinical and biological significance of TROY (TNFRSF19) splice variants in colorectal cancer.

Mitsuaki Nishioka, Yuki Kunimune, Yutaka Suehiro, Masaki Kodama, Akiyo Ishiguro, Tatsuya Takagi, Jun Nishikawa, Hidenori Takahashi, Hiroto Matsui, Shinobu Tomochika and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mitsuaki NishiokaDivision of Laboratory, Yamaguchi University Hospital, Ube, Yamaguchi 755-8505, Japan.
Yuki KunimuneDivision of Laboratory, Yamaguchi University Hospital, Ube, Yamaguchi 755-8505, Japan.
Yutaka SuehiroDivision of Laboratory, Yamaguchi University Hospital, Ube, Yamaguchi 755-8505, Japan.
Masaki KodamaDivision of Laboratory, Yamaguchi University Hospital, Ube, Yamaguchi 755-8505, Japan.
Akiyo IshiguroDepartment of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Tatsuya TakagiFaculty of Laboratory Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Jun NishikawaFaculty of Laboratory Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Hidenori TakahashiDepartment of Gastroenterological, Breast, and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Hiroto MatsuiDepartment of Gastroenterological, Breast, and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Shinobu TomochikaDepartment of Gastroenterological, Breast, and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Koichi HamabeDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Shinichi HashimotoDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Hiroaki NaganoDepartment of Gastroenterological, Breast, and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Taro TakamiDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Takahiro YamasakiDivision of Laboratory, Yamaguchi University Hospital, Ube, Yamaguchi 755-8505, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) remains a major cause of cancer-related mortality worldwide, and the development of reliable biomarkers for postoperative recurrence risk stratification is urgently required. TROY (also known as tumor necrosis factor receptor superfamily member 19) is a Wnt/β-catenin-regulated receptor implicated in tumor progression; however, to the best of our knowledge, its isoform-specific biological functions and clinical importance have not been defined. The present study examined the roles of the two major splice variants, TROY variant 1 (TROYv1) and TROY variant 2 (TROYv2), in CRC through integrated functional assays and clinical analyses.

Indexed as

colorectal cancerprognostic markerrecurrenceTROY variant 1tumor progression

Identifiers

PMID42500606
PMCPMC13396903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.